Capital International Investors’s Adaptive Biotechnologies ADPT Stock Holding History

Capital International Investors’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,093,732	Closed	-$58.8M	–	454
2021 Q4	$58.8M	Hold	2,093,732	–	–	0.01%	352
2021 Q3	$71.2M	Buy	2,093,732 +129,116	+7%	+$4.67M	0.02%	326
2021 Q2	$80.3M	Buy	1,964,616 +131,812	+7%	+$5.12M	0.02%	320
2021 Q1	$73.8M	Buy	1,832,804 +69,852	+4%	+$3.78M	0.02%	313
2020 Q4	$104M	Buy	1,762,952 +34,202	+2%	+$1.76M	0.03%	276
2020 Q3	$84.1M	Buy	1,728,750 +106,846	+7%	+$4.49M	0.03%	279
2020 Q2	$78.5M	Buy	1,621,904 +99,800	+7%	+$3.64M	0.03%	275
2020 Q1	$42.3M	Buy	1,522,104 +922,104	+154%	+$25.7M	0.02%	272
2019 Q4	$18M	Hold	600,000	–	–	0.01%	325
2019 Q3	$18.5M	Hold	600,000	–	–	0.01%	327
2019 Q2	$29M	Buy	+600,000	New	+$26.6M	0.01%	310

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Capital International Investors's ADPT Position: Q1 2022 in Review

Capital International Investors sold out of Adaptive Biotechnologies (ADPT) in Q1 2022, closing a stake of 2,093,732 shares — an estimated $58.8M sold.

Capital International Investors first reported a position in ADPT in Q2 2019 and held it in 11 quarters. The position peaked at $104M in Q4 2020. 222 funds tracked by Wall St. Rank hold ADPT as of Q1 2022.

Capital International Investors reported no remaining Adaptive Biotechnologies position as of Q1 2022 after selling out during the quarter.
Capital International Investors sold 2,093,732 Adaptive Biotechnologies shares in Q1 2022, an estimated $58.8M.
Capital International Investors first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 11 quarters.
Capital International Investors's Adaptive Biotechnologies position peaked at $104M in Q4 2020.
222 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2022.

Based on Capital International Investors's 13F filing for Q1 2022, filed 16 May 2022.